½ÃÀ庸°í¼­
»óǰÄÚµå
1598793

¿ä½Ç±Ý ±â±â ½ÃÀå : Á¦Ç° À¯Çü, Ä«Å×°í¸®, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Urinary Incontinence Device Market by Product, Incontinence Type, Category, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 184 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¿ä½Ç±Ý ±â±â ½ÃÀåÀº 2023³â 41¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2024³â¿¡´Â 44¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 8.21% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 72¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿ä½Ç±Ý ±â±â´Â ºñÀÚ¹ßÀûÀÎ ¼Òº¯ ´©ÃâÀ» °ü¸®Çϱâ À§ÇØ °í¾ÈµÈ Á¦Ç°À¸·Î, Àü ¼¼°èÀûÀ¸·Î ¼ö¹é¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â ÁúȯÀ¸·Î ÁÖ·Î ³ëÀΰú Ãâ»ê ÈÄ ¿©¼º¿¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù. Ä«Å×ÅÍ, ½½¸µ, Àΰø ¿äµµ °ý¾à±Ù, Àü±â Àڱر⠵îÀÌ Æ÷ÇԵǸç, °³ÀÎÀÇ Æí¾ÈÇÔ°ú Á¸¾ö¼ºÀ» À¯ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ Çʿ並 ÃæÁ·½ÃÄÑÁÝ´Ï´Ù. Àα¸ °í·ÉÈ­¿Í Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿ä½Ç±Ý À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â±â ½ÃÀåÀº Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä »ç¿ëó´Â º´¿ø°ú ¿Ü·¡ ¼ö¼ú ¼¾ÅͺÎÅÍ Àç°¡ ¿ä¾ç¿ø±îÁö ´Ù¾çÇϸç, ÆíÀǼº°ú ºñ¿ë È¿À²¼ºÀÌ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯¸ÁÇÑ Àü¸Á¿¡µµ ºÒ±¸Çϰí, ³ôÀº ±â±â ºñ¿ë, ±î´Ù·Î¿î ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, °ú¼ÒÁø´Ü°ú °ú¼ÒÄ¡·áÀÇ ¿øÀÎÀÌ µÇ´Â »çȸÀû ³«ÀÎ µî ½ÃÀå È®´ë¿¡ °É¸²µ¹µµ ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Ä¡·á¿Í ¸ÂÃãÇü Ä¡·á ¼Ö·ç¼ÇÀÇ Çõ½ÅÀº ±ÍÁßÇÑ ±âȸ¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, À¯È¿¼º °³¼±, °æÁ¦¼º, ȯÀÚ Á᫐ ¼³°è¿¡ ´ëÇÑ ¿¬±¸ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¾Û ±â¹Ý ¹è¼³¹° °ü¸® ÇÁ·Î±×·¥À̳ª ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿þ¾î·¯ºí ±â¼ú°ú °°Àº µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀ» Ȱ¿ëÇϸé ȯÀÚÀÇ ¼øÀÀµµ¿Í °á°ú¸¦ ´õ¿í Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº ¼ÒÇüÈ­, »ýüÀûÇÕ¼º Àç·á, ½º¸¶Æ® ¼¾¼­ ÅëÇÕ°ú °°Àº ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ±â±âÀÇ ¼º´É°ú »ç¿ëÀÚ ÆíÀǼºÀÌ Çâ»óµÊ¿¡ µû¶ó ÃËÁøµÉ °ÍÀÔ´Ï´Ù. ±×·¯³ª °³¹ßµµ»ó±¹ÀÇ ÀÇ·á Á¤Ã¥ÀÇ ºÒ±ÕÇü°ú °æÁ¦Àû Á¦¾àÀº ¿©ÀüÈ÷ µµÀü°úÁ¦·Î ³²¾ÆÀÖ½À´Ï´Ù. ±â¾÷µéÀº ÀÌ·¯ÇÑ À庮À» ±Øº¹Çϱâ À§ÇØ ¿ä½Ç±Ý Á¦Ç°ÀÇ ÀåÁ¡°ú °¡¿ë¼º¿¡ ´ëÇØ ÀÇ·áÁø°ú ȯÀÚµéÀ» ±³À°ÇÏ´Â µ¥ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ÇコÄɾî ÀÌÇØ°ü°èÀÚ¿ÍÀÇ ÆÄÆ®³Ê½Ê°ú ÷´Ü ½Å°æ ÀÚ±Ø ¿ä¹ý ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ´Â Á¦Ç° Â÷º°È­¸¦ ÃËÁøÇÏ°í ¾÷°è ¸®´õ½ÊÀ» °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¿ä½Ç±Ý ±â±â ½ÃÀåÀº Àü·«Àû Çõ½Å°ú Á¢±Ù¼º Çâ»óÀ» ÅëÇØ º¯È­ÇÒ Áغñ°¡ µÇ¾î ÀÖÀ¸¸ç, ȯÀÚ Âü¿©¿Í Á¾ÇÕÀûÀÎ Ä¡·á Àü·«À» ¿ì¼±½ÃÇÏ´Â ±â¾÷µéÀº »ó´çÇÑ ¼ºÀå ÀáÀç·ÂÀ» À̲ø¾î ³¾ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 41¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 44¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 72¾ï ´Þ·¯
CAGR(%) 8.21%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¿ä½Ç±Ý ±â±â ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¿ä½Ç±Ý ±â±â ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ³ëÀÎ Àα¸¿Í ¿ä½Ç±Ý ±â±â º¸±Þ·ü Áõ°¡
    • ÃÖ¼Òħ½À¼ö¼ú ¼ö¿ä¿Í Á¦Ç° °³¹ß
    • Á¦Ç°ÀÇ °¡¿ë¼º ¹× FDA ½ÂÀÎ Áõ°¡·Î ÀÎÇÑ »ó¾÷È­ ÃËÁø
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ¿ä½Ç±Ý ȯÀÚ Áõ°¡
  • ½ÃÀå ±âȸ
    • ¿ä½Ç±Ý ÀåºñÀÇ ±â¼ú ¹ßÀü Áõ°¡
    • ¿äµµ ½½¸µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå °úÁ¦
    • ¿ä½Ç±Ý¿¡ ´ëÇÑ ³·Àº Àνİú »çȸÀû ³«Àΰ¨
    • ½Ã¼ú·Î ÀÎÇÑ ¾Ë·ÁÁöÁö ¾ÊÀº À§Çè°ú ÇÕº´Áõ

Porter's Five Forces : ¿ä½Ç±Ý ±â±â ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÏ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¿ä½Ç±Ý ±â±â ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¿ä½Ç±Ý ±â±â ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¿ä½Ç±Ý ±â±â ½ÃÀå¿¡¼­ÀÇ °æÀï »óȲ ÆÄ¾Ç

¿ä½Ç±Ý ±â±â ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¿ä½Ç±Ý ±â±â ½ÃÀå¿¡¼­ÀÇ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¿ä½Ç±Ý ±â±â ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ¿ä½Ç±Ý ±â±â ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

¿ä½Ç±Ý ±â±â ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¿ä½Ç±Ý ±â±â ½ÃÀå : Á¦Ç°º°

  • Àΰø ¿äµµ °ý¾à±Ù
  • Àü±â Àڱرâ
  • ÆÐµå¿Í ¼ºÀÎ¿ë ±âÀú±Í
  • ¿äµµ ½½¸µ
  • ¿äµµ Ä«Å×ÅÍ
  • Áú ½½¸µ
    • ÷´Ü Áú ½½¸µ
    • ±âÁ¸ Áú ½½¸µ

Á¦7Àå ¿ä½Ç±Ý ±â±â ½ÃÀå ¿ä½Ç±Ý À¯Çüº°

  • ±â´É¼º ¿ä½Ç±Ý
  • ÀÏ·ù¼º ¿ä½Ç±Ý
  • º¹¾Ð¼º ¿ä½Ç±Ý
  • °­Á¦ ¹è´¢

Á¦8Àå ¿ä½Ç±Ý ±â±â ½ÃÀå : Ä«Å×°í¸®º°

  • ¿Ü¿ë ¿ä½Ç±Ý ±â±¸
  • ³»ºÎ ¿ä½Ç±Ý Àåºñ

Á¦9Àå ¿ä½Ç±Ý ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Ŭ¸®´Ð
  • ÀçÅà ÄÉ¾î ¼³Á¤
  • º´¿ø

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¿ä½Ç±Ý ±â±â ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ä½Ç±Ý ±â±â ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿ä½Ç±Ý ±â±â ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Aeroflow Urology
  • Atlantic Therapeutics
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Carewell
  • Coloplast A/S
  • HDIS
  • Hollister Incorporated
  • Home Care Delivered
  • Medline At Home
  • Medtronic PLC
  • Men's Liberty
  • Northshore Care Supply
  • PROMEDON GmbH
  • Teleflex Incorporated
  • TotalDry
  • Tranquility Products
  • Zephyr Surgical Implants
ksm 24.11.29

The Urinary Incontinence Device Market was valued at USD 4.14 billion in 2023, expected to reach USD 4.48 billion in 2024, and is projected to grow at a CAGR of 8.21%, to USD 7.20 billion by 2030.

Urinary incontinence devices refer to products designed to manage involuntary leakage of urine, a condition affecting millions worldwide, predominantly older adults and women post-childbirth. These devices include catheters, slings, artificial urinary sphincters, and electrical stimulation devices, fulfilling a crucial need in enabling individuals to maintain comfort and dignity. As the prevalence of urinary incontinence rises, driven by aging populations and increased awareness of treatment options, the market for these devices is set for substantial growth. Key applications span from hospitals and ambulatory surgical centers to home care settings, where convenience and cost-effectiveness drive demand. Despite the promising outlook, market expansion faces hurdles such as high device costs, stringent regulatory approvals, and social stigma contributing to underdiagnosis and undertreatment. Innovations in non-invasive treatments and personalized care solutions present valuable opportunities, underscoring the need for research into improved efficacy, affordability, and patient-centric design. Leveraging digital health solutions, such as app-based continence management programs and wearable technologies for real-time monitoring, could further enhance patient compliance and outcomes. Market growth is stimulated by technological advancements such as miniaturization, biocompatible materials, and smart sensor integration, which enhance device performance and user comfort. However, healthcare policy variability and economic constraints in developing regions remain challenges. Companies should focus on educating healthcare providers and patients about the benefits and availability of incontinence products to overcome these barriers. Partnerships with healthcare stakeholders and investment in R&D for cutting-edge neurostimulation therapies can foster product differentiation and drive industry leadership. Overall, the urinary incontinence device market is poised for transformation through strategic innovation and enhanced accessibility, with businesses prioritizing patient engagement and comprehensive care strategies to unlock substantial growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 4.14 billion
Estimated Year [2024] USD 4.48 billion
Forecast Year [2030] USD 7.20 billion
CAGR (%) 8.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urinary Incontinence Device Market

The Urinary Incontinence Device Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Geriatric population and increasing prevalence of urinary incontinence devices
    • Demand for minimally invasive surgery and product development
    • Increased product availability and FDA approvals thriving commercialization
  • Market Restraints
    • Increase in the unaware incontinent patient population
  • Market Opportunities
    • Increasing technological advancements in urinary incontinence devices
    • Growing demand for Urethral Slings
  • Market Challenges
    • Limited awareness and social stigma associated with the disease
    • Unknown risks and complications from the procedures

Porter's Five Forces: A Strategic Tool for Navigating the Urinary Incontinence Device Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urinary Incontinence Device Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urinary Incontinence Device Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urinary Incontinence Device Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urinary Incontinence Device Market

A detailed market share analysis in the Urinary Incontinence Device Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urinary Incontinence Device Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urinary Incontinence Device Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Urinary Incontinence Device Market

A strategic analysis of the Urinary Incontinence Device Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Urinary Incontinence Device Market, highlighting leading vendors and their innovative profiles. These include Aeroflow Urology, Atlantic Therapeutics, B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, Carewell, Coloplast A/S, HDIS, Hollister Incorporated, Home Care Delivered, Medline At Home, Medtronic PLC, Men's Liberty, Northshore Care Supply, PROMEDON GmbH, Teleflex Incorporated, TotalDry, Tranquility Products, and Zephyr Surgical Implants.

Market Segmentation & Coverage

This research report categorizes the Urinary Incontinence Device Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Artificial Urinary Sphincters, Electrical Stimulation Devices, Pads & Adult Diapers, Urethral Slings, Urinary Catheters, and Vaginal Slings. The Vaginal Slings is further studied across Advanced Vaginal Slings and Conventional Vaginal Slings.
  • Based on Incontinence Type, market is studied across Functional Incontinence, Overflow Incontinence, Stress Incontinence, and Urge Continence.
  • Based on Category, market is studied across External Urinary Incontinence Devices and Internal Urinary Incontinence Devices.
  • Based on End-User, market is studied across Clinics, Home care settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Geriatric population and increasing prevalence of urinary incontinence devices
      • 5.1.1.2. Demand for minimally invasive surgery and product development
      • 5.1.1.3. Increased product availability and FDA approvals thriving commercialization
    • 5.1.2. Restraints
      • 5.1.2.1. Increase in the unaware incontinent patient population
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing technological advancements in urinary incontinence devices
      • 5.1.3.2. Growing demand for Urethral Slings
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and social stigma associated with the disease
      • 5.1.4.2. Unknown risks and complications from the procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Urinary Incontinence Device Market, by Product

  • 6.1. Introduction
  • 6.2. Artificial Urinary Sphincters
  • 6.3. Electrical Stimulation Devices
  • 6.4. Pads & Adult Diapers
  • 6.5. Urethral Slings
  • 6.6. Urinary Catheters
  • 6.7. Vaginal Slings
    • 6.7.1. Advanced Vaginal Slings
    • 6.7.2. Conventional Vaginal Slings

7. Urinary Incontinence Device Market, by Incontinence Type

  • 7.1. Introduction
  • 7.2. Functional Incontinence
  • 7.3. Overflow Incontinence
  • 7.4. Stress Incontinence
  • 7.5. Urge Continence

8. Urinary Incontinence Device Market, by Category

  • 8.1. Introduction
  • 8.2. External Urinary Incontinence Devices
  • 8.3. Internal Urinary Incontinence Devices

9. Urinary Incontinence Device Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Home care settings
  • 9.4. Hospitals

10. Americas Urinary Incontinence Device Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Urinary Incontinence Device Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Urinary Incontinence Device Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aeroflow Urology
  • 2. Atlantic Therapeutics
  • 3. B. Braun Melsungen AG
  • 4. Becton, Dickinson and Company
  • 5. Boston Scientific Corporation
  • 6. Carewell
  • 7. Coloplast A/S
  • 8. HDIS
  • 9. Hollister Incorporated
  • 10. Home Care Delivered
  • 11. Medline At Home
  • 12. Medtronic PLC
  • 13. Men's Liberty
  • 14. Northshore Care Supply
  • 15. PROMEDON GmbH
  • 16. Teleflex Incorporated
  • 17. TotalDry
  • 18. Tranquility Products
  • 19. Zephyr Surgical Implants
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦